Morgan Stanley Downgrades Novartis AG (ADR) to Underperform

Brokerage firm Morgan Stanley Downgrades its rating on Novartis AG (ADR)(NYSE:NVS). The shares have been rated Underperform. Previously, the analysts had a Equal-weight rating on the shares. The rating by Morgan Stanley was issued on Apr 12, 2016.

In a different note, On Apr 1, 2016, UBS said it Downgrades its rating on Novartis AG (ADR). The shares have been rated ‘Neutral’ by the firm. On Mar 29, 2016, Citigroup said it Downgrades its rating on Novartis AG (ADR). The shares have been rated ‘Neutral’ by the firm. On Mar 23, 2016, Leerink Swann said it Downgrades its rating on Novartis AG (ADR). In the research note, the firm Lowers the price-target to $98.00 per share. The shares have been rated ‘Market Perform’ by the firm.

Novartis AG (ADR) (NVS) shares turned negative on Fridays trading session with the shares closing down -0.44 points or -0.58% at a volume of 20,91,347. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $75.74. The peak price level was also seen at $75.74 while the days lowest was $75.14. Finally the shares closed at $75.65. The 52-week high of the shares is $106.84 while the 52-week low is $69.895. According to the latest information available, the market cap of the company is $179,585 M.

Novartis AG (ADR)(NVS) last announced its earnings results on Jan 27, 2016 for Fiscal Year 2015 and Q4.Company reported revenue of $12.52B. Analysts had an estimated revenue of $12.78B. Earnings per share were $1.14. Analysts had estimated an EPS of $1.22.

Novartis AG is a holding company that through its subsidiaries is engaged in development manufacturing and marketing of a range of healthcare products led by pharmaceuticals around the world. Its portfolio includes medicines eye care generic pharmaceuticals preventive vaccines and over-the-counter (OTC) products. The Company’s segments include Pharmaceuticals which include patent-protected prescription medicines; Alcon which include surgical ophthalmic pharmaceutical and vision care products; Sandoz which include generic pharmaceuticals and Consumer Health which includes the OTC Division. Pharmaceuticals products include Afinitor/Votubia Exjade Galvus Exforge and Voltaren among others. Its Sandoz products include Valsartan (Diovan) Cyclophosphamide injection and AirFluSal Forspiro among others. Its OTC offers readily available consumer medicine. The Company operates Admune Therapeutics as a wholly owned subsidiary.

Leave a Reply

Novartis AG (ADR) - Is it time to Sell?

Top Brokerage Firms are advising their investors on Novartis AG (ADR). Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.